group G), 38 Streptococcus pneumoniae (13 With the exception of the following, all the above strains had been isolated recently from specimens from patients at or attending The Royal Free Hospital: methicillin-resistant S. aureus (MRSA) were taken at random from our worldwide collection, and the vancomycin-resistant E. faecalis were kindly given by Dr A. Uttley, Dulwich Public Health Laboratory. The cefotaxime-resistant strains had been isolated during an earlier survey. 7 
Microbiological methods
Bacto Supplement C was from Difco Laboratories, Moseley, UK, and other media from Unipath Ltd, Basingstoke, UK. MICs were determined by plate dilution. The conditions used are shown in Table I . An inoculum of 1 L was deposited on the surface of plates of Mueller-Hinton agar containing appropriate concentrations of various antibiotics, using a multipoint inoculator. An inoculum of 10 6 cfu was used for all species except H. influenzae, for which the inoculum size was 10 4 cfu. For Men 10700 and ritipenem only, an inoculum of 10 4 cfu was also used. MBCs were determined for Men 10700 and ritipenem only, by replicating from plates inoculated with 10 6 cfu with velvet pads to fresh medium as indicated in Table I . Growth of 10 colonies per spot was taken as indicating a kill of at least 99.9%.
Analysis
The concentrations of each antibiotic required to inhibit 50% and 90% of the strains tested, the parameters I 50 and B 50 , 8 and geometric means of MICs and MBCs (when possible) were calculated.
The size of the inoculum effect was calculated for each 
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species by dividing the geometric means (or, if this was not available, the I 50 ) for the 10 6 cfu inoculum by the corresponding figure for the 10 4 cfu inoculum. Ratios of B 50 /I 50 gave an indication of the bactericidal activities of Men 10700 and ritipenem. Table II , where results are for an inoculum size of 10 6 cfu for all the strains tested, except for H. influenzae (see above). The magnitude of the inoculum effect, and bactericidal activity are shown in Tables III and IV, respectively. It is clear that Men 10700 has activity against a wide range of commonly found human pathogens. Preliminary experiments showed that Men 10700, in common with other penems, had negligible activity against E. faecium, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
Results
MICs are shown in
Comparing the two penems, Men 10700 is, on a weightto-weight basis, six-to ten-fold more active against Enterobacter spp., C. freundii and the selected cefotaxime-resistant strains (65% of which belonged to the latter two genera), and two to three times more active against methicillin-sensitive staphylococci, -haemolytic streptococci, E. coli, M. morganii, P. stuartii, P. rettgeri and S. marcescens. It is of similar or lower potency against E. faecalis, K. pneumoniae, Protens. vulgaris, Acinetobacter spp., H. influenzae, M. catarrhalis and the anaerobes tested. Both penems were bactericidal at or near their MIC against all the species tested except for S. aureus. The latter appeared tolerant to both penems. On the other hand, MBCs for half the E. faecalis strains tested were 16 mg/L. Increasing the inoculum size had little effect, except in the case of the MRSA; the latter finding is presumably a reflection of the heterogeneity of the strains tested.
Compared with the other compounds tested, Men 10700 was superior to ciprofloxacin against the methicillin-sensitive staphylococci and the streptococci, but was less active against the Gram-negative species. Men 10700 was superior to amikacin against the methicillin-sensitive staphylococci, streptococci, enterococci, E. coli, K. pneumoniae and M. catarrhalis; the two compounds were of similar activity against Enterobacter spp., C. freundii, P. mirabilis, P. vulgaris, P. rettgeri, S. marcescens, Acinetobacter spp. and the cefotaxime-resistant strains. Coamoxiclav was superior only against the enterococci, P. mirabilis, P. vulgaris and clostridia. Men 10700 had greater in-vitro activity than cefotaxime against staphylococci, E. faecalis, Enterobacter spp., C. freundii, Acinetobacter spp., cefotaxime-resistant strains and M. catarrhalis.
Discussion
The penems under development can be administered by both parenteral and oral routes (either as such or in the form of pro-drugs), a considerable advantage over the carbapenems. They seem sufficiently stable to renal dehydropeptidase to allow them to be given without an inhibitor of the latter enzyme. 5 While penems lack the antipseudomonal activity of the carbapenems, they compare very favourably in their antibacterial spectrum with oral third-generation cephalosporins, 9 especially against staphylococci and Gram-negative anaerobes. Further advantages over the cephalosporins are their stability to -lactamases, an ability to inhibit many such enzymes and poor selective power for derepressed mutants. 10 Men 10700 has promising in-vitro characteristics. It is active against a wide range of clinically isolated pathogens, in concentrations that should be attainable in vivo with the type of dosage regimen customary for -lactam antibiotics. For example, a concentration of 8 mg/L will inhibit the vast majority of the 539 strains tested, with the exception (not surprisingly) of the MRSA. It retains useful activity against strains known to be resistant to other antibiotics, shows a minimal inoculum effect, and is usually bactericidal at or near its MIC. Men 10700 appeared to be active against some strains of MRSA, a finding also made in respect of ritipenem. 11 The clinical significance of this is, however, unclear, especially as ritipenem has a low affinity for penicillin-binding protein (PBP) 2 in MRSA. 12 Men 10700 was superior to the related compound ritipenem (as reported here) and to f a r o p e n e m 9 against several species, most markedly E n t e r obacter spp. and Citrobacter spp.
A particularly encouraging finding was the useful activity of Men 10700 against strains selected for testing because of their acquired resistance. The cefotaximeresistant strains, which we 7 had previously found to be resistant to several other broad-spectrum -lactam antibiotics (ceftazidime, ticarcillin/clavulanate, temocillin, aztreonam), were more sensitive to Men 10700 than to ritipenem. Men 10700 was as active as cefotaxime against 13 penicillin-resistant pneumococci. Vancomycin-resistant E. faecalis were only slightly less sensitive to Men 10700 than their vancomycin-sensitive counterparts.
Penems in the same chemical series as Men 10700 have been shown to target PBP2 in E. coli, and their small size and compactness means that they penetrate the outer membrane of this species with ease. 13 An orally available prodrug of Men 10700 is currently being developed (Menarini Spa, personal communica- tion). It is hoped that this will allow oral switch therapy to be instigated in the future. The limited in-vitro data indicate that Men 10700 is superior to ritipenem and faropenem in several respects, and appears an attractive alternative to carbapenems when antipseudomonal activity is not essential and oral therapy is desirable. 
